Drug Development

ACTRIMS-ECTRIMS 2014 -- Day 2, afternoon

More tweets from the largest MS research meeting ever

The afternoon continues with a news conference on progressive MS funding, a poster session, three...

Clinical Research, Drug Development, Laboratory Research, Meetings, Methods, People

International Progressive MS Alliance Announces New Research Grants

An international group committed to advancing research and treatment in progressive MS has announced €22 million in grants

The International Progressive MS Alliance today announced its first round of 22 grants to...

Clinical Research, Drug Development, Laboratory Research, Meetings, Methods, People

ACTRIMS-ECTRIMS 2014 -- Day 2, morning

The tweets are coming hot and heavy!

The opening ceremony, Plenary Session 1, and three parallel sessions are featured...

Clinical Research, Drug Development, Laboratory Research, Meetings, Methods, People

ACTRIMS-ECTRIMS 2014 -- Day 1, afternoon

The afternoon sessions on Day 1 included the Charcot Symposium, two Young Investigators symposia, and a Burning Debate

Live blogging from #msboston2014 has commenced! Find out what #MSresearch Dr. Nicholas LaRocca is...

Clinical Research, Drug Development, Laboratory Research, Meetings, Methods, People

ACTRIMS-ECTRIMS 2014 -- Day 1, morning

The Americas and European Committees for Research and Treatment in Multiple Sclerosis are meeting in Boston, September 10-13, 2014

Multiple Sclerosis Discovery Forum staffers Bob Finn, Carol Cruzan Morton, and Cynthia McKelvey and freelancer Dan Keller will be...

Clinical Research, Drug Development, Laboratory Research, Meetings, Methods, People

MS Patient, Ph.D.: Lightning (and the Ice Bucket Challenge) Doesn’t Strike Twice

The ice bucket challenge has raised $100 million for the ALS Association; should the MS community try to copy this campaign?

In the past month, my Facebook feed has been full of videos of friends dropping...

Clinical Research, Drug Development, Laboratory Research

Phase 1 Results Reported for Anti-LINGO-1 Remyelination Agent

BIIB033, a monoclonal antibody targeting the LINGO-1 remyelination signaling block, passes phase 1 safety tests

A high-profile experimental treatment to repair the damaged myelin around nerves in people with...

Clinical Research, Drug Development

MS Research Roundup: August 21, 2014

MS Therapeutics Consensus Paper; Dusting Off Old Drugs; Countdown to ACTRIM-ECTRIMS in Boston; Warming Up to the Ice Bucket Challenge

Items of interest to multiple sclerosis researchers from around the Web...

Drug Development, Meetings

MS Research Roundup: August 18, 2014

U.S. Plegridy Approval; Red Blood Cells to Deliver Drugs; Corruption and Unproven MS Supplement; Anxiety of Multiple Sclerosis

Items of interest to multiple sclerosis researchers from around the Web...

Drug Development, Laboratory Research, People

MS Research Roundup: August 8, 2014

Myelin Drug Pipeline; Old, Obscure, and Expensive; Progressive MS Self-Portraits

Items of interest to multiple sclerosis researchers from around the Web...

Drug Development, People

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

User Top Menu

ACTRIMS-ECTRIMS 2014 -- Day 2, afternoon

International Progressive MS Alliance Announces New Research Grants

ACTRIMS-ECTRIMS 2014 -- Day 2, morning

ACTRIMS-ECTRIMS 2014 -- Day 1, afternoon

ACTRIMS-ECTRIMS 2014 -- Day 1, morning

MS Patient, Ph.D.: Lightning (and the Ice Bucket Challenge) Doesn’t Strike Twice

Phase 1 Results Reported for Anti-LINGO-1 Remyelination Agent

MS Research Roundup: August 21, 2014

MS Research Roundup: August 18, 2014

MS Research Roundup: August 8, 2014

Pages

MSDF Footer

Search form

Drug Development

Pages